BLLN vs NTRA
BLLN: BillionToOne uses breakthrough single-molecule sequencing technology to detect sparse disease signals in blood with unprecedented precision for prenatal and cancer diagnostics. NTRA: Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health.
Side-by-side fundamentals
| Metric | BLLN | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $129.24 | $264.22 | |
| Market cap as of 2026-07-23 | $6.0B | $37.9B | |
| P/E as of 2026-07-23 | 237.82 | n/a | |
| PEG as of 2026-07-23 | n/a | -13.63 | |
| Net margin as of 2026-07-23 | +6.2% | -9.1% | BLLN higher |
| Gross margin as of 2026-07-23 | +69.5% | +65.1% | BLLN higher |
| Operating margin as of 2026-07-23 | +8.2% | -13.0% | BLLN higher |
| ROE as of 2026-07-23 | +7.6% | -15.1% | BLLN higher |
| ROA as of 2026-07-23 | +5.1% | -10.5% | BLLN higher |
| Debt / equity as of 2026-07-23 | 0.20 | 0.05 | NTRA lower |
| Revenue growth (YoY) as of 2026-07-23 | -37.0% | +36.6% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +106.2% | +41.1% | BLLN higher |
| Beta as of 2026-07-23 | 0.98 | 1.54 | |
| 1-year return as of 2026-07-22 close | +61.9% | +88.8% | NTRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.